Prevalence of phosphodiesterase-5 inhibitor use in the VHA in 2004 and 2005 is twice that of a commercial health plan in 2001
- PMID: 17269850
- PMCID: PMC10438309
- DOI: 10.18553/jmcp.2006.12.8.692
Prevalence of phosphodiesterase-5 inhibitor use in the VHA in 2004 and 2005 is twice that of a commercial health plan in 2001
Comment on
-
Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil.J Manag Care Pharm. 2005 Oct;11(8):674-80. doi: 10.18553/jmcp.2005.11.8.674. J Manag Care Pharm. 2005. PMID: 16194131 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources